

Jennifer S Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3953627/publications.pdf>

Version: 2024-02-01

83
papers

6,604
citations

230014

27
h-index

78623

77
g-index

85
all docs

85
docs citations

85
times ranked

7187
citing authors

#	ARTICLE	IF	CITATIONS
1	Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 220-231.	1.0	7
2	A systematic review of the evidence supporting post-operative antithrombotic use following cardiopulmonary bypass in children with CHD. <i>Cardiology in the Young</i> , 2022, 32, 10-20.	0.4	1
3	Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination. <i>Circulation</i> , 2022, 145, 345-356.	1.6	132
4	Causes of Death in Infants and Children with Congenital Heart Disease. <i>Pediatric Cardiology</i> , 2021, 42, 1308-1315.	0.6	8
5	Individuals aged 1-64 years with documented congenital heart defects at healthcare encounters, five U.S. surveillance sites, 2011-2013. <i>American Heart Journal</i> , 2021, 238, 100-108.	1.2	10
6	Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms. <i>Journal of Pediatrics</i> , 2021, , .	0.9	2
7	Weight-Related Behaviors of Children with Obesity during the COVID-19 Pandemic. <i>Childhood Obesity</i> , 2021, 17, 371-378.	0.8	54
8	Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. <i>Journal of the American Heart Association</i> , 2021, 10, e021765.	1.6	32
9	Risk Factors for Sudden Infant Death in North Carolina. <i>Frontiers in Pediatrics</i> , 2021, 9, 770803.	0.9	2
10	The Bayley-III scale may underestimate neurodevelopmental disability after cardiac surgery in infants. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, 63-71.	0.6	13
11	A Randomized, Controlled Pharmacokinetic and Pharmacodynamics Trial of Ambrisentan After Fontan Surgery. <i>Pediatric Critical Care Medicine</i> , 2020, 21, e795-e803.	0.2	10
12	Clinical and socio-economic predictors of work participation in adult CHD patients. <i>Cardiology in the Young</i> , 2020, 30, 1081-1085.	0.4	4
13	Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. <i>Journal of Pediatrics</i> , 2020, 222, 213-220.e5.	0.9	8
14	Pulmonary Valve Endocarditis: The Potential Utility of Multimodal Imaging Prior to Surgery. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2020, 11, 192-197.	0.3	3
15	Rationale and design of "Hearts & Parks" study protocol for a pragmatic randomized clinical trial of an integrated clinic-community intervention to treat pediatric obesity. <i>BMC Pediatrics</i> , 2020, 20, 308.	0.7	6
16	Flattening the (BMI) Curve: Timing of Child Obesity Onset and Cardiovascular Risk. <i>Pediatrics</i> , 2020, 146, e20201353.	1.0	4
17	Behavior and Quality of Life at 6 Years for Children With Hypoplastic Left Heart Syndrome. <i>Pediatrics</i> , 2019, 144, .	1.0	25
18	Acid Suppression Therapy and Symptom Improvement (or Lack Thereof) in Children. <i>Pediatrics</i> , 2019, 144, e20190909.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the Tj ETQq1 1 0.784314 rgBT /Oerlock	1.0	23
20	Research Gaps in Primary Pediatric Hypertension. <i>Pediatrics</i> , 2019, 143, .	1.0	23
21	Agreement of an echocardiogram-based diagnosis of pulmonary hypertension in infants at risk for bronchopulmonary dysplasia among masked reviewers. <i>Journal of Perinatology</i> , 2019, 39, 248-255.	0.9	17
22	Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	23
23	Severe Cardiac Involvement Is Rare in Patients with Late-Onset Pompe Disease and the Common c.-32-13T>G Variant: Implications for Newborn Screening. <i>Journal of Pediatrics</i> , 2018, 198, 308-312.	0.9	21
24	Effect of renal function on antihypertensive drug safety and efficacy in children. <i>Pediatric Nephrology</i> , 2018, 33, 139-146.	0.9	5
25	Changes in Drug Development Regulations and Their Impact on Clinical Trials. , 2018, , 841-852.		0
26	Impact of imaging approach on radiation dose and associated cancer risk in children undergoing cardiac catheterization. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 888-897.	0.7	14
27	Congenital Heart Disease in Premature Infants 25-32 Weeks' Gestational Age. <i>Journal of Pediatrics</i> , 2017, 181, 37-41.e1.	0.9	46
28	Maladaptive aortic properties after the Norwood procedure: An angiographic analysis of the Pediatric Heart Network Single Ventricle Reconstruction Trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 471-479.e3.	0.4	14
29	Severe Cardiomyopathy as the Isolated Presenting Feature in an Adult with Late-Onset Pompe Disease: A Case Report. <i>JIMD Reports</i> , 2016, 31, 79-83.	0.7	20
30	Cardiopulmonary resuscitation in hospitalized infants. <i>Early Human Development</i> , 2016, 101, 17-22.	0.8	13
31	Childhood Hypertension: An Underappreciated Epidemic?. <i>Pediatrics</i> , 2016, 138, e20162857-e20162857.	1.0	10
32	Clinicians' Adherence to Guidelines on Evaluation of Hypertension in Children and Adolescents. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2016, 7, 440-445.	0.3	2
33	Changes in Drug Development Regulations and Their Impact on Clinical Trials. , 2016, , 1-12.		0
34	Paediatric cardiovascular clinical trials: an analysis of ClinicalTrials.gov and the Food and Drug Administration Pediatric Drug Labeling Database. <i>Cardiology in the Young</i> , 2015, 25, 172-180.	0.4	12
35	Neurodevelopmental Outcomes After Cardiac Surgery in Infancy. <i>Pediatrics</i> , 2015, 135, 816-825.	1.0	392
36	Response to Letters Regarding Article, "Cumulative Radiation Exposure and Cancer Risk Estimation in Children With Heart Disease". <i>Circulation</i> , 2015, 131, e419-20.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Implementation of Management Strategies for Diabetes and Hypertension: From Local to Global Health in Cardiovascular Diseases. <i>Global Heart</i> , 2015, 10, 31.	0.9	12
38	Cumulative Radiation Exposure and Cancer Risk Estimation in Children With Heart Disease. <i>Circulation</i> , 2014, 130, 161-167.	1.6	192
39	Longitudinal Assessment of Growth in Hypoplastic Left Heart Syndrome: Results From the Single Ventricle Reconstruction Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e000079.	1.6	63
40	Comparative Effectiveness of Digoxin and Propranolol for Supraventricular Tachycardia in Infants*. <i>Pediatric Critical Care Medicine</i> , 2014, 15, 839-845.	0.2	18
41	Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. <i>American Heart Journal</i> , 2014, 167, 921-929.e2.	1.2	31
42	Excess Costs Associated With Complications and Prolonged Length of Stay After Congenital Heart Surgery. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1660-1666.	0.7	79
43	Challenges and Priorities for Research. <i>Circulation</i> , 2014, 130, 1192-1203.	1.6	28
44	Pediatric exclusivity and other contemporary regulatory initiatives: aligning financial incentives with the needs of our patients. <i>Clinical Investigation</i> , 2014, 4, 989-991.	0.0	2
45	Pediatric trials of antihypertensive agents: impact of trial design and unique pediatric factors on efficacy end points. <i>Clinical Investigation</i> , 2014, 4, 1031-1041.	0.0	2
46	Clopidogrel in Infants with Systemic-to-Pulmonary-Artery Shunts. <i>New England Journal of Medicine</i> , 2013, 368, 2377-2384.	13.9	57
47	Changes in Pediatric Food and Drug Administration Written Requests and Regulations: Impact on Clinical Trial of Hypertension Trials in Children. , 2013, , 573-582.		0
48	Status of the Pediatric Clinical Trials Enterprise: An Analysis of the US ClinicalTrials.gov Registry. <i>Pediatrics</i> , 2012, 130, e1269-e1277.	1.0	78
49	Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: A comparative study of platelet aggregation response. <i>Platelets</i> , 2012, 23, 430-438.	1.1	10
50	Perioperative Methylprednisolone and Outcome in Neonates Undergoing Heart Surgery. <i>Pediatrics</i> , 2012, 129, e385-e391.	1.0	101
51	Opportunities and challenges in linking information across databases in pediatric cardiovascular medicine. <i>Progress in Pediatric Cardiology</i> , 2012, 33, 21-24.	0.2	14
52	Clinical Research Careers: Reports from a NHLBI Pediatric Heart Network Clinical Research Skills Development Conference. <i>American Heart Journal</i> , 2011, 161, 13-67.	1.2	9
53	Lessons learned from a pediatric clinical trial: The Pediatric Heart Network Angiotensin-Converting Enzyme Inhibition in Mitral Regurgitation Study. <i>American Heart Journal</i> , 2011, 161, 233-240.	1.2	27
54	Pediatric Cardiovascular Drug Trials, Lessons Learned. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 4-8.	0.8	20

#	ARTICLE	IF	CITATIONS
55	Pediatric Antihypertensive Clinical Trials. , 2011, , 575-585.		0
56	Antiplatelet Therapy in Pediatric Cardiovascular Patients. Pediatric Cardiology, 2010, 31, 454-461.	0.6	14
57	The Efficacy and Safety of the Novel Aldosterone Antagonist Eplerenone in Children with Hypertension: A Randomized, Double-Blind, Dose-Response Study. Journal of Pediatrics, 2010, 157, 282-287.	0.9	48
58	Partial and Transitional Atrioventricular Septal Defect Outcomes. Annals of Thoracic Surgery, 2010, 89, 530-536.	0.7	47
59	Safety of Aprotinin in Congenital Heart Operations: Results from a Large Multicenter Database. Annals of Thoracic Surgery, 2010, 90, 14-21.	0.7	52
60	Platelet Activity Associated with Concomitant Use of Clopidogrel and Proton Pump Inhibitors in Children with Cardiovascular Disease. Congenital Heart Disease, 2010, 5, 552-555.	0.0	7
61	Laboratory Measures of Exercise Capacity and Ventricular Characteristics and Function Are Weakly Associated With Functional Health Status After Fontan Procedure. Circulation, 2010, 121, 34-42.	1.6	42
62	Globalization of Pediatric Research: Analysis of Clinical Trials Completed for Pediatric Exclusivity. Pediatrics, 2010, 126, e687-e692.	1.0	40
63	Fluticasone propionate/salmeterol combination in children with asthma: Key cardiac and overall safety results. Clinical Research and Regulatory Affairs, 2010, 27, 87-95.	2.1	8
64	Safety and Transparency of Pediatric Drug Trials. JAMA Pediatrics, 2009, 163, 1080-6.	3.6	60
65	The economic returns of pediatric clinical trials of antihypertensive drugs. American Heart Journal, 2008, 156, 682-688.	1.2	23
66	Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children. Circulation, 2008, 117, 553-559.	1.6	135
67	Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity. Pediatrics, 2008, 122, e628-e633.	1.0	36
68	Pediatric Antihypertensive Trial Failures. Hypertension, 2008, 51, 834-840.	1.3	117
69	Response to Letter Regarding Article, "Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children: Primary Results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial". Circulation, 2008, 118, .	1.6	0
70	Safety of Placebo Controls in Pediatric Hypertension Trials. Hypertension, 2008, 51, 829-833.	1.3	19
71	Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program. JAMA - Journal of the American Medical Association, 2007, 297, 480.	3.8	148
72	Rationale and design of a randomized clinical trial of β -blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. American Heart Journal, 2007, 154, 624-631.	1.2	217

#	ARTICLE	IF	CITATIONS
73	Clinical Outcomes of Palliative Surgery Including a Systemic-to-Pulmonary Artery Shunt in Infants With Cyanotic Congenital Heart Disease. <i>Circulation</i> , 2007, 116, 293-297.	1.6	142
74	Is pediatric exclusivity working?. <i>Pediatric Health</i> , 2007, 1, 43-49.	0.3	3
75	Peer-Reviewed Publication of Clinical Trials Completed for Pediatric Exclusivity. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1266.	3.8	134
76	The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 649-654.	0.6	34
77	Is the Extrapolated Adult Dose of Fosinopril Safe and Effective in Treating Hypertensive Children?. <i>Hypertension</i> , 2004, 44, 289-293.	1.3	67
78	Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. <i>American Heart Journal</i> , 2004, 147, 173-180.	1.2	27
79	Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. <i>American Heart Journal</i> , 2002, 144, 608-614.	1.2	26
80	Real-Time Volumetric Echocardiography. <i>Echocardiography</i> , 2000, 17, 773-779.	0.3	56
81	Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis. <i>Clinical Infectious Diseases</i> , 2000, 30, 633-638.	2.9	3,392
82	Etiology and danger of pericardial effusion in infants and children. <i>Cardiology in the Young</i> , 1996, 6, 162-165.	0.4	4
83	Relation of left ventricular mass, volume and mass/volume ratio in children with aortic stenosis and/or insufficiency. <i>Cardiology in the Young</i> , 1995, 5, 105-109.	0.4	0